These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 16234113)

  • 1. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
    Zheng H; Luo RC
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic value of combined detection of TPS, NSE and CEA in lung cancer].
    Zheng H; He BF; Luo RC
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Feb; 23(2):165-6. PubMed ID: 12581971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
    Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
    Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of serum tissue polypeptide-specific antigen in breast cancer].
    Zheng H; He BF; Luo RC; You CX; Mai GF; Lu HF
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):823-5. PubMed ID: 12919909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA.
    Willsher PC; Beaver J; Blamey RW; Robertson JF
    Anticancer Res; 1995; 15(4):1609-11. PubMed ID: 7654057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and prognostic significance of preoperative serum CA153, CEA and TPS levels in patients with primary breast cancer].
    Chen Y; Zheng YH; Lin YY; Hu MH; Chen YS
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):842-6. PubMed ID: 22335950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
    Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
    Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical value of combined detection of LDH, TPS, CEA and beta2-MG in patients with non- Hodgkin's lymphoma].
    Chen W; Luo RC; Fan WW; Ma SD
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):227-8, 230. PubMed ID: 16503538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
    Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
    Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients.
    Schuurman JJ; Bong SB; Einarsson R
    Anticancer Res; 1996; 16(4B):2169-72. PubMed ID: 8694538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical value of combined determination of serum and pleural effusion level of CEA,CYFRA21-1, TPS in the diagnosis of lung cancer].
    Huang F; Wang XL; Yang L; Yin BX; Geng Y; Li TT
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr; 24(4):370-2. PubMed ID: 18394347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
    Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
    Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
    Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF
    Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
    Hu XC; Day W; Jones B; Loo WT; Chow LW
    Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
    Pan QR; Zhang X; Xu ZF; Zheng S
    Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
    Sütterlin M; Bussen S; Trott S; Caffier H
    Anticancer Res; 1999; 19(4A):2567-70. PubMed ID: 10470196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.
    Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K
    Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Detection of serum S100 protein and tissue polypeptide-specific antigen for diagnosis and treatment of breast cancer].
    Luo RC; He XB; Cai HB; Li AM
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Jan; 24(1):102-4. PubMed ID: 14724113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
    Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.